Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 5
2014 39
2015 31
2016 35
2017 32
2018 33
2019 47
2020 27
2021 18
2022 20
2023 16
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Johnston R, et al. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. Health Technol Assess. 2017. PMID: 28105986 Free PMC article. Review.
If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. ...OBJECTIVE: To review the clinical effectiveness and …
If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which c …
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. Tsapas A, et al. Ann Intern Med. 2020 Aug 18;173(4):278-286. doi: 10.7326/M20-0864. Epub 2020 Jun 30. Ann Intern Med. 2020. PMID: 32598218
Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 trials). ...Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to …
Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on …
Anti-ageing effects of FDA-approved medicines: a focused review.
Thanapairoje K, Junsiritrakhoon S, Wichaiyo S, Osman MA, Supharattanasitthi W. Thanapairoje K, et al. J Basic Clin Physiol Pharmacol. 2023 Jan 13;34(3):277-289. doi: 10.1515/jbcpp-2022-0242. eCollection 2023 May 1. J Basic Clin Physiol Pharmacol. 2023. PMID: 36631934 Review.
This review focused on describing in vivo anti-ageing activity of US-FDA-approved drugs and found that alogliptin, canagliflozin and metformin might produce anti-ageing activity via AMPK activation. ...Other indirect mechanisms, including insulin-lowering effect by …
This review focused on describing in vivo anti-ageing activity of US-FDA-approved drugs and found that alogliptin, canagliflozin and …
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Zhang J, Xing C, Cheng X, He B. Zhang J, et al. Front Endocrinol (Lausanne). 2022 Sep 6;13:1003238. doi: 10.3389/fendo.2022.1003238. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36147577 Free PMC article. Clinical Trial.
OBJECTIVES: Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated, and it could become a novel option in the PCOS treatment. ...This randomiz …
OBJECTIVES: Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monot …
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.
Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Murata K. Ida S, et al. Curr Diabetes Rev. 2021;17(3):293-303. doi: 10.2174/1573399816666200705210006. Curr Diabetes Rev. 2021. PMID: 32628589
Metformin did not show a significant decrease in FFM compared with the placebo. When compared with the placebo, semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss. CONCLUSION: Although semaglutide, dapaglifrozin, and can …
Metformin did not show a significant decrease in FFM compared with the placebo. When compared with the placebo, semaglutide, dapaglif …
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Lazzaroni E, et al. Pharmacol Res. 2021 Sep;171:105782. doi: 10.1016/j.phrs.2021.105782. Epub 2021 Jul 22. Pharmacol Res. 2021. PMID: 34302978 Free article.
RESULTS: Our results suggested that anti-diabetic drugs can be stratified into 3 groups based on their efficacy in weight loss: metformin, acarbose, empagliflozin and exenatide resulted in a in a mild weight loss (less than 3.2% of initial weight); canagliflozin, er …
RESULTS: Our results suggested that anti-diabetic drugs can be stratified into 3 groups based on their efficacy in weight loss: metformin …
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ. Lingvay I, et al. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17. Lancet Diabetes Endocrinol. 2019. PMID: 31540867 Clinical Trial.
Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA(1c) 7.0-10.5% [53-91 mmol/mol]) on stable daily metformin therapy. Patients were randomly assigned (1:1) by use of an interactive web response system to subcutaneous semaglutide 1.0 mg o …
Eligible patients were at least 18 years old and had uncontrolled type 2 diabetes (HbA(1c) 7.0-10.5% [53-91 mmol/mol]) on stable daily me …
Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect.
Corremans R, Vervaet BA, Dams G, D'Haese PC, Verhulst A. Corremans R, et al. Int J Mol Sci. 2023 May 20;24(10):9043. doi: 10.3390/ijms24109043. Int J Mol Sci. 2023. PMID: 37240387 Free PMC article.
The current study compares the renoprotective potential of metformin, canagliflozin, metformin + canagliflozin, and quercetin in a preclinical rat model of DKD. ...After two weeks, rats were assigned to five treatment groups, receiving vehicle, metf …
The current study compares the renoprotective potential of metformin, canagliflozin, metformin + canagliflozin, …
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Seferović PM, et al. Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8. Eur J Heart Fail. 2018. PMID: 29520964 Free article. Review.
Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and insulin have been the traditional second- and third-line therapies although their safety in HF is equivocal. ...In recent trials, sodium-glu …
Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and …
Antidiabetic Agents.
[No authors listed] [No authors listed] 2017 Jun 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jun 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644090 Free Books & Documents. Review.
First line conventional therapies for type 2 diabetes include biguanides (metformin) and sulfonylureas. Metformin increases insulin sensitivity whereas the sulfonylureas increase insulin secretion. ...A relatively new category of antidiabetic agents are inhibitors o …
First line conventional therapies for type 2 diabetes include biguanides (metformin) and sulfonylureas. Metformin increases in …
281 results